Angiotensin III (human, mouse): Atomic Evidence for RAAS, Receptor Signaling, and Disease Models

Executive Summary: Angiotensin III (human, mouse) (CAS: 13602-53-4) is a biologically active hexapeptide, generated by N-terminal cleavage of angiotensin II, and retains full aldosterone-stimulating capability while mediating approximately 40% of the pressor activity of angiotensin II (Oliveira et al., 2025). It interacts with both AT1 and AT2 receptors, showing relative specificity for AT2, and elicits pressor and dipsogenic responses in rodent models. Exogenous administration suppresses renin and robustly induces aldosterone secretion, paralleling angiotensin II effects. The peptide is highly soluble and stable as a solid, making it suitable for diverse cardiovascular and neuroendocrine workflows (APExBIO).

Biological Rationale

Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe) is a central effector peptide within the renin-angiotensin-aldosterone system (RAAS), formed by the enzymatic removal of the N-terminal Asp residue from angiotensin II by aminopeptidases in erythrocytes and tissues (Oliveira et al., 2025). The RAAS regulates blood pressure, electrolyte homeostasis, and systemic vascular resistance. Angiotensin III acts on both AT1 and AT2 receptor subtypes, with a higher relative affinity for AT2, compared to its precursor. In vivo, it is responsible for approximately 40% of the pressor effect of angiotensin II but maintains full aldosterone-releasing activity (APExBIO’s Angiotensin III: Precision RAAS Peptide). This duality enables precise experimental modeling of differential RAAS receptor signaling, hypertension, and neuroendocrine regulation.

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III binds to both AT1 and AT2 receptors, both of which are G protein-coupled receptors. AT1 receptor activation mediates vasoconstriction, sodium retention, and aldosterone secretion. AT2 receptor activation is associated with vasodilation, anti-fibrotic, and anti-inflammatory effects (Oliveira et al., 2025). Angiotensin III displays a unique functional profile: it retains full aldosterone-stimulating activity but exerts only a partial pressor effect (about 40% relative to angiotensin II at equimolar concentrations). In rodent models, administration of exogenous Angiotensin III induces both pressor and dipsogenic responses and suppresses renin release. The physiological and pharmacological actions of Angiotensin III are context-dependent, determined by receptor expression patterns and tissue localization. Notably, Angiotensin III does not require further enzymatic processing for receptor engagement, unlike longer angiotensin peptides.

Evidence & Benchmarks

• Angiotensin III is produced by N-terminal cleavage of angiotensin II via aminopeptidase A activity in tissues and erythrocytes (Oliveira et al., 2025).
• This peptide retains full aldosterone-inducing capacity but mediates only 40% of the vasopressor activity of angiotensin II in vivo (Angiotensin III: Core RAAS Peptide).
• Angiotensin III acts as a ligand for both AT1 and AT2 receptors, with a higher specificity for AT2 relative to angiotensin II (Oliveira et al., 2025).
• Experimental administration in rodents triggers aldosterone secretion and suppresses renin release, paralleling angiotensin II but with distinct receptor bias (APExBIO’s Angiotensin III: Precision RAAS Peptide).
• Angiotensin III is highly soluble: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO (at 25°C, pH 7.4), facilitating diverse experimental workflows (APExBIO).
• It is stable as a lyophilized solid at -20°C for over 12 months and is not recommended for long-term storage in solution (APExBIO).
• Shorter N-terminal angiotensin peptides, such as Angiotensin III, can enhance viral spike protein–AXL binding, with implications for COVID-19 pathogenesis (Oliveira et al., 2025).

This article extends the mechanistic insights presented in "Angiotensin III (human, mouse): Advanced Insights for Cardiovascular and Viral Pathogenesis" by focusing on atomic, verifiable facts, and clarifies the solubility and storage boundaries highlighted in "Angiotensin III: Core RAAS Peptide for Cardiovascular Research".

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is a key tool for:

• Modeling RAAS signaling in cardiovascular and hypertension research (APExBIO Mechanistic Catalyst).
• Dissecting AT1 vs. AT2 receptor-specific effects in neuroendocrine and renal studies.
• Validating aldosterone and renin feedback in bench and in vivo models.
• Exploring peptide–viral receptor interactions in infectious disease/viral entry studies.

Common Pitfalls or Misconceptions

• Angiotensin III does not fully replicate the vasopressor potency of angiotensin II; it mediates ~40% of the effect at equivalent doses (Oliveira et al., 2025).
• It is not suitable for long-term solution storage; degradation accelerates above -20°C or in aqueous buffers over time (APExBIO).
• Angiotensin III is not a direct AT1-selective ligand; it has higher AT2 receptor specificity compared to angiotensin II.
• Peptide modifications (e.g., phosphorylation) can alter receptor affinity and biological effects, and must be validated independently.
• Use in viral pathogenesis models requires context-specific controls, as effects on viral spike–host receptor binding may not extrapolate to in vivo infectivity (Oliveira et al., 2025).

Workflow Integration & Parameters

Angiotensin III (human, mouse) is supplied as a solid (MW 931.09 Da, C₄₆H₆₆N₁₂O₉) and should be stored desiccated at -20°C. Reconstitution is recommended in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), or DMSO (≥93.1 mg/mL) at neutral pH and room temperature. For optimal performance, prepare fresh solutions before use; avoid repeated freeze-thaw cycles. The peptide is compatible with standard in vitro and in vivo RAAS protocols. For mechanistic studies, titrate concentrations to dissect AT1 vs. AT2 receptor effects. Refer to the A1043 kit for detailed technical data and solubility tables. For protocol innovations and troubleshooting, see "Angiotensin III: Powerful RAAS Peptide for Cardiovascular Research", which this article updates with new evidence on viral pathogenesis and peptide storage.

Conclusion & Outlook

Angiotensin III (human, mouse) is a benchmark RAAS peptide, validated for dissecting AT1 and AT2 receptor signaling, aldosterone induction, and cardiovascular modeling. Its high solubility, robust stability as a solid, and well-characterized receptor profile enable precise experimental design. APExBIO supplies rigorously characterized Angiotensin III as SKU A1043, supporting advanced cardiovascular, neuroendocrine, and infectious disease research (APExBIO). Ongoing studies on peptide–viral receptor interactions may further expand its translational relevance, but careful attention to peptide handling and experimental context is critical. For further reading, compare with the mechanistic overviews in APExBIO Mechanistic Catalyst.